A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

Neuropsychopharmacology

Volumn 29, Issue 1, 2004, Pages 133-145

  Sikich, Linmarie ^a   Hamer, Robert M ^a,b   Bashford, Robert A ^a   Sheitman, Brian B ^a,c   Lieberman, Jeffrey A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c Dorothea Dix Hospital   (United States)

Author keywords

Adolescent; Antipsychotic agents; Childhood schizophrenia; Olanzapine; Psychotic disorders; Risperidone

Indexed keywords

AMANTADINE; AMFEBUTAMONE; BENZATROPINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; OLANZAPINE; PAROXETINE; RISPERIDONE; SERTRALINE; TRAZODONE; TRIHEXYPHENIDYL; VALPROIC ACID; VENLAFAXINE;

ADOLESCENT; ADULT; AKATHISIA; ANALYTIC METHOD; ARTICLE; BLOOD TOXICITY; BODY MASS; BREAST TUMOR; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG PREFERENCE; DRUG TOLERABILITY; DYSTONIA; DYSURIA; ENERGY METABOLISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART RHYTHM; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NERVOUSNESS; PAIN; PARKINSONISM; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REDUCTION; SCHOOL CHILD; SEDATION; SIDE EFFECT; SWEATING; TARDIVE DYSKINESIA; THORAX PAIN; TITRIMETRY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINE RETENTION; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; MALE; PILOT PROJECTS; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0346688561     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300327     Document Type: Article

References (45)

1. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL (2002). Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159: 1337-1346.
2. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62: 239-248.
3. Buitelaar JK, Willemsen-Swinkels SH (2000). Medication treatment in subjects with autistic spectrum disorders. Eur Child Adolesc Psychiatry 9(Suppl 1): 185-197.
4. CDC (2002). http://www.cdc.gov/nccdphp/dnpa/bmi/bmi-forage.htm, September 2002, CDC BMI for age tables.
5. Chambers W, Puig-Antich J, Hirsch M, Paez P, Ambrosini J, Tabrizi MA (1985). The assessment of affective disorders in children and adolescents by semi-structured interview: test-retest reliability of the Schedule for Affective Disorders and Schizophrenia for school-age children, present episode version. Arch Gen Psychiatry 42: 696-702.
6. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM (2002). A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 41: 1216-1223.
7. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T et al (1997). A double-blind, randomized placebo-controlled trial of fluoxetine in depressed children and adolescents. Arch Gen Psychiatry 54: 1031-1037.
8. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000). A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 3: 509-516.
9. First MB, Gibbon M, Spitzer RL, Williams J (1997). Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinician Version. American Psychiatric Press, Inc.: Washington, DC.
10. Fish B (1985). Children's Psychiatric Rating Scale. Psychopharmacol Bull 21: 753-770.
11. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology Revised DHEW Pub. No. (ADM) 76-338. National Institute of Mental Health: Rockville, MD.
12. Henderson DC (2002). Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents. Curr Diabet Reports 2: 135-140.
13. Hughes CW, Rintelmann J, Emslie GJ, Lopez M, MacCabe N (2001). A revised anchored version of the BPRS-C for childhood psychiatric disorders. J Child Adol Psychopharmacol 11: 77-93.
14. Kafantaris V, Coletti DJ, Dicker R, Padula G, Kane JM (2001a). Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatry 40: 1448-1456.
15. Kafantaris V, Dicker R, Coletti DJ, Kane JM (2001b). Adjunctive antipsychotic treatmen is necessary for adolescents with psychotic mania. J Child Adolesc Psychopharmacol 11: 409-413.
16. Keepers GA, Clappison VJ, Casey DE (1983). Initial anticholinergic prophylaxis for acute neuroleptic induced extrapyramidal syndromes. Arch Gen Psychiatry 40: 1113-1117.
17. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM (1998). Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8: 151-159.
18. Kumra S (2000). The diagnosis and treatment of children and adolescents with schizophrenia: My mind is playing tricks on me. Child Adolesc Psychiatric Clin North Am 9: 183-199.
19. Kumra S, Frazier JA, Jacobsen L, McKenna K, Gordon CT, Lenane M et al (1996). Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53: 1090-1097.
20. Lieberman JA (1996). Atypical antipsychotic drugs as a first line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 57(s11): 68-71.
21. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA (2001). Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40: 887-894.
22. Malone RP, Sheikh R, Zito JM (1999). Novel antipsychotic medications in the treatment of children and adolescents. Psychiatr Serv 50: 171-174.
23. Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L et al (2000). Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 10: 259-268.
24. McClellan J, McCurry C, Speltz ML, Jones K (2002). Symptom factors in early-onset psychotic disorders. J Am Acad Child Adolesc Psychiatry 41: 791-798.
25. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Research Units on Pediatric Psychopharmacology Autism Network et al (2002). Risperidone in children with autism and serious behavioral problems. N Engl J Med 347: 314-321.
26. McKenna K, Gordon CT, Lenane M, Kaysen D, Fahey K, Rapoport JL (1994). Looking for childhood onset schizophrenia: the first 71 cases screened. J Am Acad Child Adolesc Psychiatry 33: 636-644.
27. Munetz MR, Benjamin S (1988). How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 39: 1172-1177.
28. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP et al (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59: 337-345.
29. Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychol Rep 10: 799-812.
30. Overall JE, Pfefferbaum B (1982). The Brief Psychiatric Rating Scale for children. Psychopharmacol Bull 18: 10-16.
31. PMATSLS2 (2002). http://www.IMShealth.com, Retail & Provider Perspective Audit (PMATSLS2).
32. Pool D, Bloom W, Mielke DH, Roniger Jr JJ, Gallant DM (1976). A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 19: 99-104.
33. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G et al (2002). Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41: 337-343.
34. Remschmidt H, Hennighausen K, Clement HW, Heiser P, Schulz E (2000). Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 9(Suppl 1): 9-19.
35. Rosner B (1995). Hypothesis testing: categorical data. In: Wadswort Publishing Company (eds). Fundamentals of Biostatistics. Belmont: CA.
36. Selva KA, Scott SM (2001). Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 138: 936-938.
37. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159: 561-566.
38. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212(Suppl): 11-19.
39. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A (2002). The Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41: 1026-1036.
40. Spencer EK, Alpert M, Pouget ER (1994). Scales for the assessment of neuroleptic response in schizophrenic children: specific measures derived from the CPRS. Psychopharmacol Bull 30: 199-202.
41. Spencer EK, Campbell M (1994). Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy. Schizophr Bull 20: 713-725.
42. Toren P, Laor N, Weizman A (1998). Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry 59: 644-656.
43. Werry JS, McClellan J, Chard L (1991). Early-onset schizophrenia, bipolar and schizoaffective disorders: a clinical follow-up study. J Am Acad Child Adolesc Psychiatry 30: 457-465.
44. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC (1998). Novel antipsychotics and new onset diabetes. Biol Psychiatry 44: 778-783.
45. Wudarsky M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J et al (1999). Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9: 239-245.